Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity. Academic Article uri icon

Overview

abstract

  • Adenomyoepitheliomas (AMEs) of the breast are uncommon and span the morphologic spectrum of benign, atypical, in situ, and invasive forms. In exceptionally rare cases, these tumors metastasize to regional lymph nodes or distant sites. In the era of genomic characterization, data is limited regarding AMEs. The aim of this study was to provide insight into the molecular underpinnings of a spectrum of AMEs. Seven cases of AMEs of the breast (benign-1, atypical-2, in situ-1, invasive-3) were identified in our files. The seven samples were interrogated using the Oncomine Comprehensive Assay v3 (ThermoFisher). Two atypical AMEs and the malignant in situ AME harbored the same gain-of-function PIK3CA mutation. The malignant in situ AME also showed EGFR amplification, not described previously. Both a benign AME and a malignant invasive AME shared the same gain-of-function AKT1 variant. The benign AME also showed a GNAS mutation. Moreover, the same gain-of-function HRAS mutation was present in an atypical AME and a malignant invasive AME. We also identified co-occurring HRAS and PIK3CA mutations in an ER-positive atypical AME, which has not been previously described. No fusion drivers were detected. We describe the molecular characteristics of the spectrum of AME tumors of the breast, which harbor alterations in the PI3K/AKT pathway. Our findings are clinically relevant with respect to the current options of targeted therapy in the rare instances where malignant AME tumors of the breast progress.

publication date

  • April 30, 2020

Research

keywords

  • Adenomyoepithelioma
  • Breast Neoplasms
  • Class I Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt

Identity

Scopus Document Identifier

  • 85084206367

Digital Object Identifier (DOI)

  • 10.1016/j.ajpath.2015.09.004

PubMed ID

  • 32355271

Additional Document Info

volume

  • 33

issue

  • 9